Could a cancer drug slow bile duct tumors?

NCT ID NCT04645160

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by mouth in 28-day cycles and are monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tivozanib (a drug that blocks blood vessel growth to tumors)
What this could lead to: If it works, this could provide a new treatment option for people with bile duct cancer who have already tried chemotherapy.
What could go wrong: This is an early-phase trial with only 31 participants, so results may not apply to everyone. The drug may cause side effects like high blood pressure or may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILE DUCT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct neoplasm biliary tract cancer cholangiocarcinoma gallbladder cancer hereditary sensory and autonomic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILE DUCT NEOPLASM BILIARY TRACT MALIGNANCY CHOLANGIOCARCINOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.